Author(s): Fraga NA, Paim Mde F, Follador I, Ramos AN, Rgo VR
Abstract Share this page
Abstract Psoriasis affects 0.12\% to 0.71\% of all children. Erythrodermic psoriasis is an uncommon but serious disorder, occurring in less than 1.5\% of cases. Tumor necrosis factor-alpha blockers (TNF-α) are a new class of drugs used to treat moderate to severe psoriasis refractory to conventional therapies. Etanercept is a TNFα receptor fusion protein, approved by the FDA for treating juvenile rheumatoid arthritis. We present the case of a 7-year-old suffering from plaque psoriasis since 8 months old which evolved into erythroderma refractory to cyclosporine and methotrexate. Patient responded excellently to etanercept, with no adverse side effects.
This article was published in An Bras Dermatol
and referenced in Journal of Clinical & Experimental Dermatology Research